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Abstract
Summary Once-weekly administration of 56.5 μg teriparatide
improved cortical bone parameters and biomechanical param-
eters at the proximal femur by CT geometry analysis.
Introduction The aim of this study was to evaluate the effects
of weekly administration of teriparatide [human PTH (1–34)]
on bone geometry, volumetric bone mineral density
(vBMD), and parameters of bone strength at the proximal
femur which were longitudinally investigated using computed
tomography (CT).
Methods The subjects were a subgroup of a recent, randomly
assigned, double-blind study (578 subjects) comparing the
anti-fracture efficacy of a once-weekly subcutaneous injection
of 56.5 μg teriparatide with placebo (TOWER trial).
Results Sixty-six ambulatory postmenopausal women with
osteoporosis were enrolled at 15 study sites having multi-
detector row CT, and included women injected with
teriparatide (n =29, 74.2±5.1 years) or with placebo (n =37,
74.8±5.3 years). CT data were obtained at baseline and
follow-up scans were performed at 48 and 72 weeks. The data
were analyzed to obtain cross-sectional densitometric, geo-
metric, and biomechanical parameters including the section
modulus (SM) and buckling ratio (BR) of the femoral neck,
inter-trochanter, and femoral shaft. We found that once-
weekly teriparatide increased cortical thickness/cross-
sectional area (CSA) and total area, and improved biomechan-
ical properties (i.e., decreasing BR) at the femoral neck and
shaft. Teriparatide did not change the cortical perimeter.
Conclusions Our longitudinal analysis of proximal femur ge-
ometry by CT revealed that once-weekly administration of
56.5 μg teriparatide improved cortical bone parameters at the
femoral neck and shaft and also improved biomechanical
parameters.
Keywords Once-weekly injection . Osteoporosis . Proximal
femur geometry . Quantitative computed tomography .
Teriparatide
Introduction
Parathyroid hormone (PTH) stimulates bone formation and
resorption and can increase or decrease bone mass, depending
on the dose and timing of administration. Continuous infu-
sions and daily subcutaneous injections of teriparatide stimu-
late bone formation but have distinct effects on bone
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resorption and bone mass [1, 2]. Daily injections of 20 and
40 μg teriparatide increased the bone mineral density (BMD)
at the lumbar spine by 9 and 13 %, and reduced the risk of
incident vertebral fractures by 65 and 69 % as relative risk
reduction, respectively, as compared with placebo [3].
Weekly injections of 56.5 μg teriparatide have been shown
to increase BMD at the lumbar spine by 8.1 % after 48 weeks
of treatment as determined by dual energy X-ray absorptiom-
etry (DXA) [4]. Anti-fracture efficacy of once-weekly subcu-
taneous injection of 56.5 μg teriparatide for 72 weeks was
evaluated in 578 postmenopausal women and older men with
primary osteoporosis by a randomized controlled trial, the
Teriparatide Once-Weekly Efficacy Research (TOWER) trial
[5]. Vertebral fracture risk was reduced by 80% as relative risk
reduction.
Daily treatment with teriparatide reduced the risk of non-
vertebral fractures by 35 to 40 % at the 20 and 40 μg dose,
respectively, and reduced the risk of non-vertebral fragility
fractures by 53 and 54 %, respectively [3]. Weekly treatment
with teriparatide reduced the risk of clinical fragility fractures
include non-vertebra by 67 % [5].
The bone geometry in the proximal femur is thought to be
strongly related to bone strength, and our previous studies
showed that proximal femur geometrical parameters could
predict the incidence of neck fracture or inter-trochanter frac-
ture [6].
The reason for reduced risk of non-vertebral fracture may
be explained by changes in structure and biomechanical prop-
erties by teriparatide treatment. Therefore, it is important to
evaluate changes in structure and mechanical properties in
each treatment regimen of teriparatide compared to the
placebo.
As a surrogate endpoint of the TOWER trial, computed
tomography (CT) has been applied to evaluate and compare
the effects of teriparatide versus placebo on proximal femur,
since CTevaluation is considered to be a suitable cortical bone
assessment. The purpose of this study was to investigate the
effect of once-weekly injection of 56.5μg teriparatide on bone
geometry, volumetric bone density, and bone strength param-
eters of the proximal femur, using CT.
Methods
Subjects
Subjects in this study were a subset of the original TOWER
trial [5], and constituted ambulatory female patients with
osteoporosis enrolled at 15 study sites equipped with multi-
detector row CT (MDCT) to measure hip BMD, bone geom-
etry, and biomechanical indices. All subjects in this study
fulfilled the inclusion and exclusion criteria of the original
TOWER trial. Subjects with one to five vertebral fractures
with low BMD (T-score≤−1.67) at either the lumbar spine
(L2–L4), femoral neck, total hip, or radius measured by dual-
energy X-ray absorptiometry (DXA) or the right second meta-
carpal bone measured by radiographic absorptiometry were
eligible. Subjects with diseases or using drugs affecting bone
or calcium metabolism were excluded. The subjects were
randomly divided into two groups, either weekly subcutane-
ous injection of 56.5 μg teriparatide or placebo for 72 weeks.
All subjects received daily supplements of 610 mg calcium,
400 IU vitamin D3, and 30 mg magnesium.
The original trial was conducted in compliance with the
ethical principles stated in the Declaration of Helsinki and
Good Clinical Practice. The trial was approved by the institu-
tional review boards at each site and all subjects provided
written informed consent before enrollment.
CT data acquisition
CT data were obtained at baseline and follow-up scans were
performed at 48 and 72weeks of treatment, using the scanning
and reconstruction protocol previously described [7]. The
scanning conditions (X-ray energy, 120 to 140 kV; X-ray
current, 250 mA; rotation speed, 0.8 to 1.0 s/rot; beam pitch,
0.5625 to 0.9375) and reconstruction parameters were
predefined for each type of CT scanner. Beam pitch is defined
as the ratio of table feed per rotation to the collimation, where
collimation is the product of slice-thickness and the number of
slices in each rotation. Field of View (FOV) was defined as
350 mm to cover bilateral proximal femur regions. In-plane
spatial resolution of 0.625 to 0.652 mm and reconstructed
slice thickness of 0.500 to 0.625 mm were adjusted according
to CT scanner type. The CT values were converted to bone
mineral scale by using a solid reference phantom, B-MAS200
(Fujirebio Inc., Tokyo, Japan) containing hydroxyapatite
(HA) at 0, 50, 100, 150, and 200 mg/cm3.
The MDCT scanners used in this study originally included
four Asteion 4, one Aquilion 16 TSX-101A, one Aquilion 32,
and three Aquilion 64 scanners (Toshiba Medical Systems
Corporation); two LightSpeed Ultra_16, one LightSpeed
VCT_64, and one BrightSpeed Elite_16 scanner (GE-
Yokogawa Medical); and one Somatom 16, and one
Somatom 64 scanner (Siemens, AG).
Scanner cross-calibration
Good linear correlations between the CT values and HA
concentrations were demonstrated (r =0.993 to 1.000; p <
0.0006 to 0.0001) in all CTscanners. Differences in CT values
according to X-ray energy were corrected using the reference
phantom to convert CT values to HA equivalent values.
However, it was necessary to confirm the longitudinal stability
of the CT values of the threshold value used to define the
cortical bone.
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Quality assurance (QA) scans with a Type 3 Mindways
Phantom (Mindways Software, Austin, TX, USA) were per-
formed before and after study measurements took place at the
individual clinical sites in order to adjust for longitudinal
changes of the detector. QA measurements were evaluated
according to the quantitated computed tomography (QCT)-
Pro QA Guide from Mindways. There was no drift from
baseline to the completion of treatment in any CT apparatus.
Subject positioning for CT scanning
Subjects were scanned in the supine position with the refer-
ence phantom beneath them and placed so as to cover a region
from the top of the acetabulum to 4 cm below the bottom of
the lesser trochanter in each hip joint (average slice number
was 298). Buffer material to protect artifact, such as a bolus
bag or blanket, were placed between the subject and the CT
calibration phantom. The subject’s hands and arms were
placed over their head or as high on the chest as was comfort-
able to avoid interfering with the scan area. The CT scanner
table height was set to the center of the greater trochanter.
Analysis of BMD, bone geometry, and biomechanical
properties obtained by CT
Subject data were evaluated with QCT-Pro software v4.1.3
with the QCT-Pro Bone Investigational Toolkit v2.0 (BIT)
(Mindways Software) for the femoral neck, inter-trochanter,
and femoral shaft regions. All measurements were analyzed
by a radiologist (M. Ito) blinded to treatment-group
assignment.
QCT-Pro CTXA proximal femur exam analysis
The exact 3D rotation of the femur and the threshold setting
for defining the bone contours appeared to be the two most
critical steps for achieving accuracy and reproducibility in the
automated procedures performed by QCT-Pro [7, 8]. The
outer cortical margin was defined using uniform HA equiva-
lent BMD values.
The femoral neck axis was identified visually and also
automatically with the “Optimize FN Axis” algorithm.
Using the eccentricity registration method, a series of 10
reformatted 1-mm slices was positioned perpendicularly to
the neck axis. The definitions of inter-trochanter and
femoral-shaft cross-section are consistent with the DXA-
based hip structure analysis methods developed by Tom
Beck [9]. All steps were compared visually across all visits
and repeated if the positioning did not appear to be accurate.
The eccentricity registration method was applied to define
the volume of interest (VOI) consisting of six reformatted 1-
mm slices oriented perpendicular to the neck axis. QCT BIT
processing was then performed with a fixed-bone threshold
for cortical separation set to 350 mg/cm3 for all subjects and
visits. This application was used to measure hip axis length
(HAL), femoral neck angle (FNA), and neck width, vBMD,
cross-sectional area (CSA), and cross-sectional bone mass of
the femoral neck, inter-trochanter, and femoral shaft (total and
cortical regions). Cortical thickness and perimeter were also
measured. Biomechanical properties were also derived from
the cross-sectional parameters of the femoral neck, inter-
trochanter, and shaft.
Analysis of cross-sectional bone geometry and volumetric
BMD
The cross-sectional femoral neck data were based on the
geometrical axis to calculate cortical CSA (in square centime-
ter), total CSA (in square centimeter), volumetric cortical
BMD (cortical vBMD; in milligram per cubic centimeter),
total volumetric BMD (total vBMD; in milligram per cubic
centimeter), total bone mass (in gram), and cortical bone mass
(in gram). In this study, total CSAwas defined as the estimated
total mineralized area. Cortical thickness (in millimeter) and
cortical perimeter (in centimeter) were also derived.
Biomechanical parameters
Because biomechanical parameters were determined on the
principal axis, the cross-sectional moment of inertia (CSMI; in
millimeters to the fourth power), the section modulus (SM; in
cubic millimeter) and the buckling ratio (BR) were calculated
from bone density and geometrical data. The CSMI is defined
by the integration of the products of incremental CSA and the
square of their distance from the center of mass (centroid). The
SM is the ratio of CSMI to the maximal distance of the
material from the centroid, which is directly related to strength
with respect to a corresponding bending stress. Due to local
buckling, failure occurs on the compressive surface, and BR
was calculated in this study as the maximal distance from the
centroid divided by the average cortical thickness [9].
Reproducibility of the analysis done by the QCT-Pro pro-
gram was calculated by using five repeated measurements
with visual matching each time from CT data sets without
visible artifacts from seven healthy subjects. The coefficient of
variation, as determined by the root mean square standard
deviation divided by the mean, was 1.49 % for total vBMD,
2.63 % for cortical vBMD, 1.12 % for total mass, 1.71 % for
total CSA, 2.11 % for cortical CSA, 2.11 % for cortical
perimeter, and 3.58 % for cortical thickness at the femoral
neck [10].
Statistics
All statistical analyses were performed on subjects who had
been randomized and had evaluable observations for QCT
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assessment both at baseline and post-dose (48 or 72 weeks).
Paired and Student’s t tests, and chi-square test were used and
Pearson’s correlation coefficients are shown. All p values
calculated in the analysis were two-sided and were not adjust-
ed for multiple testing. Statistical analyses were done with
SAS version 9.1 (SAS Institute, Cary, USA).
Results
A total of 66 subjects were enrolled and randomly assigned to
two treatment groups. There were 29 in the teriparatide group
(age 66 to 83 years; mean ± SD, 74.2±5.1 years) and 37 in the
placebo group (age 66 to 88 years, 74.8±5.3 years). Table 1
shows the background of subjects and bone characteristics at
baseline in both groups. There were no significant differences
between the two groups in age, height, weight, body mass
index (BMI), years after menopause, BMD at the spine and
hip, or the number of vertebral fractures (p >0.05).
Effect of teriparatide on bone geometry parameters
Baseline and the observed change of bone geometry parame-
ters are shown in Table 2. There were no significant differ-
ences at baseline for any bone geometry parameter at the
femoral neck, inter-trochanter, and femoral shaft between the
teriparatide and placebo groups. Compared to baseline, week-
ly teriparatide significantly increased cortical thickness at the
femoral neck (3.5 %, 48 weeks) and shaft (2.6 %, 72 weeks).
Cortical CSA increased at the inter-trochanter (3.8 %,
48 weeks) and femoral shaft (2.7 %, 72 weeks). Total CSA
increased at the inter-trochanter (3.8 % at 48 weeks; 4.7 %,
72 weeks) and femoral shaft (2.5 %, 72 weeks). Cortical
vBMD decreased at the femoral neck (1.2 %, 72 weeks) and
inter-trochanter (1.5 %, 72 weeks). BR was also decreased at
the femoral shaft (3.3 %, 72 weeks). There was no change in
cortical perimeter at any site. There were no significant chang-
es observed in the placebo group except for an increase in BR
at the inter-trochanter (4.3 %, 48 weeks).
Effect of teriparatide on cortical thickness, cortical and total
CSA, and cortical perimeter compared to placebo
Comparisons of cortical thickness, CSA, and perimeter be-
tween the two groups are shown in Fig. 1. Significantly higher
cortical thickness was observed in the teriparatide group at the
femoral neck (48 and 72 weeks) and shaft (72 weeks)
(Fig. 1a). Significantly higher cortical CSA at the inter-
trochanter (at 48 weeks) and at the femoral neck (72 weeks)
were observed in the teriparatide group (Fig. 1b). Significantly
higher total CSA at the inter-trochanter (48 and 72 weeks) and
the femoral shaft (72 weeks) were observed in the teriparatide
group (Fig. 1c). No significant differences were observed in
the cortical perimeters between the teriparatide and placebo
groups at any measurement site (Fig. 1d).
In summary, both cortical thickness and CSA increased in
all three regions following treatment with teriparatide and
decreased in the placebo group. In contrast, there was no
change in cortical perimeter following once-weekly injections
of teriparatide.
Effect of teriparatide on cortical and total vBMD compared
to placebo
The comparison of cortical and total vBMD between the
teriparatide and placebo groups is shown in Fig. 2. No signif-
icant differences in cortical vBMDwere observed between the
groups. A significant higher total vBMD in the teriparatide
group was observed at the inter-trochanter (Fig. 2b).
Effect of teriparatide on biomechanical parameters compared
to placebo
The differences in biomechanical parameters are shown in
Fig. 3. SM changes in the teriparatide group at the three
measurement sites were positive but not significant (Fig. 3a).
BR values in the teriparatide group at the femoral neck (48 and
72 weeks) and shaft (72 weeks) were significantly lower
compared to placebo (Fig. 3b).
Relationship between changes in cortical thickness
and other parameters
In order to understand the relationships between the parame-
ters, the correlations between the percent changes in cortical
Table 1 Subject baseline demographics and bone characteristics
Teriparatide Placebo
(n =29) (n=37)
Age (years) 74.2±5.1 74.8±5.3
Body height (cm) 147.8±5.1 147.5±5.5
Body weight (kg) 50.9±8.4 49.1±8.5
Body mass index (BMI) (kg/m2) 23.3±3.5 22.5±3.5
Years after menopause (years) 24.6±6.5 25.2±6.6
Bone mineral density (T-score)
Lumbar spine (L2–4) −2.6±1.0 −2.8±0.8
Femoral neck −2.4±0.7 −2.6±0.7
Femoral total hip −2.0±1.0 −2.5±1.2
Number of prevalent vertebral fractures 1.6±1.1 1.3±1.3
Bone mineral density was measured by dual X-ray absorptiometry
Data are mean ± SD
Two subjects who were diagnosed with a BMD evaluation at the radius or
metacarpal bone in the teriparatide group and one subject evaluated at the
metacarpal bone in the placebo group were included
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thickness and those in the other parameters at the femoral neck
at 72 weeks were analyzed, since cortical thickness was most
significantly improved following once-weekly teriparatide
treatment. Percent changes in cortical thickness at the femoral
neck had significant positive correlations with percent change
of cortical CSA (r =0.612, p <0.0001), total CSA (r =0.389,
p =0.0062), total vBMD (r =0.546, p <0.0001), and SM (r =
0.523, p =0.0001) in the teriparatide group. Negative correla-
tions were found between percent changes of cortical thick-
ness and cortical perimeter (r =−0.561, p <0.0001) or BR (r =
−0.905, p <0.0001) in teriparatide group. The same trends in
the correlation between cortical thickness and the other pa-
rameters were observed in placebo group. The correlation
between percent change in cortical thickness and BR at the
femoral neck was higher in the teriparatide group (r2=0.82)
than in the placebo group (r2=0.54). There was no significant
correlation between the percent change in cortical thickness
and that of cortical vBMD in either group.
To visualize the relationships of multiple parameters at the
individual level, the percent change in cortical thickness at the
femoral neck was plotted on the horizontal axis of each panel
in Fig. 4 versus the percent changes in cortical CSA (Fig. 4a),
perimeter (Fig. 4b), SM (Fig. 4c), and BR (Fig. 4d), separately
for the teriparatide (solid lines) and placebo (dashed lines)
groups. Each panel of Fig. 4 is divided into four quadrants and
the percentages of closed circles (teriparatide) and open circles
(placebo) included in each quadrant are provided in the figure.
The linear regression lines are basically the same between the
teriparatide and placebo groups. Further, with respect to pa-
rameters with positive correlations (Fig. 4a, c), the distribution
of individual data in the teriparatide group is significantly
different from placebo (cortical CSA: p =0.0111, SM: p =
0.0250); weighted distribution of closed circles (teriparatide)
in the first quadrant is high, while the open circles (placebo)
are highly distributed in the third quadrant. Similarly, in the
case of parameters with negative correlations (Fig. 4b, d), the
Table 2 Baseline QCT measurements and the percent changes at 48 and 72 weeks
Site Parameter Teriparatide Placebo
(n =29) (n =37)
Baseline 48 weeks 72 weeks Baseline 48 weeks 72 weeks
Femoral neck Cortical thickness (mm) 1.47±0.24 3.5±7.1* 3.6±9.0 1.52±0.26 −0.5±6.8 −0.9±5.1
Cortical CSA (cm2) 0.86±0.15 2.8±7.6 2.2±7.9 0.90±0.15 −0.6±6.1 0.0±5.2
Total CSA (cm2) 1.22±0.21 2.2±7.1 3.2±7.3 1.28±0.19 −0.2±5.1 0.6±4.8
Cortical perimeter (cm) 10.96±0.97 −1.6±4.4 −1.4±5.9 10.96±0.93 0.2±3.8 0.1±3.5
Cortical vBMD (mg/cm3) 667.00±52.57 −0.6±2.7 −1.2±2.3* 676.84±46.65 −0.2±4.3 −0.8±3.1
Total vBMD (mg/cm3) 221.77±31.77 1.0±3.4 0.0±3.8 227.98±35.35 −0.7±4.4 −1.2±3.3
SM (cm3) 0.38±0.1 3.4±8.2 2.3±8.8 0.38±0.1 −0.3±8.2 0.6±7.5
BR 13.96±2.32 −3.2±7.4 −3.0±8.3 13.44±3.22 1.3±6.2 1.8±6.1
Inter-trochanter Cortical thickness (mm) 1.43±0.26 0.9±5.9 0.7±6.4 1.51±0.29 −2.3±6.6 −0.8±7.7
Cortical CSA (cm2) 1.38±0.29 3.8±7.4* 2.9±8.6 1.54±0.33 −1.6±5.6 −0.6±5.5
Total CSA (cm2) 2.38±0.45 3.8±8.8* 4.7±9.4* 2.59±0.5 −1.8±5.6 −0.6±4.8
Cortical perimeter (cm) 16.76±1.15 0.2±3.3 −0.6±2.0 17.12±1.18 0.6±2.4 0.0±2.1
Cortical vBMD (mg/cm3) 638.96±48.01 −0.4±2.4 −1.5±2.1** 646.03±44.09 −0.3±2.9 −0.6±2.4
Total vBMD (mg/cm3) 186.13±35.97 1.1±3.3 0.7±4.7 196.1±35.7 −1.5±4.5 −1.5±4.8
SM (cm3) 0.67±0.18 5.0±15.8 4.1±11.8 0.73±0.18 2.4±12.0 1.8±10.2
BR 19.71±3.6 2.1±10.2 1.8±10.7 19.26±4.41 4.3±9.5* 2.1±10.1
Femoral shaft Cortical thickness (mm) 3.71±0.62 0.7±5.1 2.6±4.5* 3.91±0.62 −0.7±4.6 −1.3±3.9
Cortical CSA (cm2) 2.22±0.39 1.7±5.2 2.7±3.6* 2.35±0.39 −0.6±4.1 −0.5±3.0
Total CSA (cm2) 2.38±0.38 1.7±5.0 2.5±3.4* 2.5±0.39 −0.5±4.0 −0.1±3.0
Cortical perimeter (cm) 10.27±0.6 0.4±3.8 −0.7±2.5 10.3±0.7 0.2±4.3 0.5±3.2
Cortical vBMD (mg/cm3) 879.65±70.77 0.4±2.7 0.1±3.6 892.97±59.03 0.3±4.1 −0.9±3.1
Total vBMD (mg/cm3) 461.36±77.37 0.7±5.1 1.1±5.7 482.05±74.95 −0.2±5.2 −1.4±4.3
SM (cm3) 0.88±0.18 1.3±5.9 2.7±7.2 0.93±0.2 −0.8±5.2 0.3±4.8
BR 3.67±0.88 −0.4±7.7 −3.3±5.4* 3.39±0.75 0.9±6.7 1.9±5.3
Data are mean ± SD
QCT quantitated computed tomography, CSA cross-sectional area, vBMD volumetric bone mineral density, SM section modulus, BR buckling ratio
* p<0.05; ** p <0.01 compared with baseline
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Fig. 1 Mean percent changes and 95% confidence interval from baseline
in cortical thickness (a), cortical cross-sectional area (CSA) (b), total
CSA (c), and cortical perimeter (d) at 48 and 72 weeks of treatment with
teriparatide and placebo. Changes at the femoral neck (FN), inter-tro-
chanter (IT), and femoral shaft (FS) are shown. Values on top of each
panel indicate p values (between teriparatide and placebo group). Red
and blue bars correspond to teriparatide and placebo groups, respectively.
To compare the difference between the two groups, the percent changes
from baseline in QCT parameters were analyzed using the Student’s t test
Fig. 2 Mean percent changes and 95% confidence interval from baseline
in cortical volumetric bone mineral density (vBMD) (a) and total vBMD
(b ) at 48 and 72 weeks of treatment with teriparatide and placebo.
Changes at the femoral neck (FN), inter-trochanter (IT), and femoral
shaft (FS) are shown. Values on top of each panel indicate p values
(between teriparatide and placebo group). Red and blue bars correspond
to teriparatide and placebo groups, respectively. To compare the differ-
ence between the two groups, the percent changes from baseline in QCT
parameters were analyzed using the Student’s t test
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distribution of closed circles (teriparatide) in the fourth quad-
rant is high, while the open circles (placebo) are highly dis-
tributed in the second quadrant. The difference between
teriparatide and placebo is significant for BR (p =0.0274).
These results suggest that changes in the placebo group with
natural aging (i.e., age-related deteriorations in proximal fe-
mur geometry and biomechanical properties) are reversed at
least partially by once-weekly teriparatide treatment.
Discussion
This longitudinal assessment by CT demonstrates the changes
in bone geometry, vBMD, and mechanical properties at the
proximal femur by once-weekly injection of 56.5 μg
teriparatide for 72 weeks. This is the first longitudinal CT
study to include comparison with a double-blinded placebo
group. Previous studies have evaluated the effects of
teriparatide on proximal femur geometry and its biomechan-
ical properties using CT [8], but they did not include a placebo
group.
Generally, the effects of once-weekly teriparatide injection
on proximal femur geometry in this study are similar to results
with daily teriparatide injections reported in a subgroup of the
EUROFORS study (EU-CT study) [8]. The same analysis
software program was employed and the main effects includ-
ed increases in cortical thickness/CSA as well as total vBMD.
Cortical thickness/CSA increasing while bone perimeter
remained unchanged over 72 weeks of once-weekly
teriparatide, suggests that cortical bone formation took place
at the endosteal surface resulting in an increase in cortical
thickness with a significant decrease in BR.
One difference observed between the weekly and daily
treatment regimens is the effect on cortical vBMD. Although
only eight patients were included in the treatment-naïve group
in the EU-CT study, daily teriparatide decreased cortical
vBMD at the femoral neck after 6 months of treatment
(∼3.0 % from baseline), which was consistent with the results
of a previous large clinical trial [11]. Moreover, a decrease in
cortical BMD at the femoral neck with 12 months of daily
teriparatide treatment [12] and a decrease in cortical BMD at
the distal radius and tibia were reported [13]. In contrast, our
results showed that once-weekly teriparatide maintained cor-
tical vBMD at the femoral neck (−0.6 %, 48 weeks and
−1.2 %, 72 weeks). This difference may be due to distinct
patterns of bone remodeling between daily and weekly
teriparatide treatment given that weekly teriparatide caused
an increase in serum osteocalcin (bone formation marker) and
a decrease in urinary NTX (bone resorption marker) [5]. Other
factors such as cohort effects, differences in CT acquisition or
the software may also have had an effect and help to explain
the differences.
The question of whether or not teriparatide stimulates peri-
osteal apposition has been raised. In the EU-CT study, total
CSA (cortical CSA plus marrow area) did not change signifi-
cantly throughout the study period and the authors concluded
that there was no detectable periosteal apposition. DXA-based
hip structure analysis (HSA), conducted as a subgroup of the
Fracture Prevention Trial (DXA-HSA study) [9], also showed
that periosteal apposition appeared to be reduced in patients
receiving daily teriparatide in comparison with a placebo-
treated group. On the other hand, some studies reported daily
treatment with teriparatide seemed to stimulate new bone for-
mation on the periosteal and endosteal surfaces [14, 15]. Thus,
periosteal and endosteal apposition may be stimulated within a
certain time window or may vary depending on skeletal sites,
such as weight bearing or non-weight bearing bone [13].
Bone generally expands in diameter with age [16, 17], as
less bone density requires a wider bone to maintain bending
strength. It has been speculated that expansion is a
Fig. 3 Mean percent changes and 95% confidence interval from baseline
in SM (a) and BR (b) at 48 and 72 weeks of treatment with teriparatide
and placebo. Changes at the femoral neck (FN), inter-trochanter (IT), and
femoral shaft (FS) are shown. Values on top of each panel indicate
p values (between teriparatide and placebo group). Red and blue bars
correspond to teriparatide and placebo groups, respectively. To compare
the difference between the two groups, the percent changes from baseline
in QCT parameters were analyzed using the Student’s t test
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homeostatic adaptation to a net bone loss in order to maintain
bone strength [18, 19]. This age-related adaptive response was
not seen in the placebo group of the current study. Once-
weekly injection of teriparatide increased cortical thickness
with no change in cortical perimeter at the femoral neck. Thus,
it is tempting to speculate that as a result of increased cortical
thickness (which improves bone strength), periosteal apposi-
tion may not be required under once-weekly teriparatide
treatment. Actually, a change in BR based upon improvement
in cortical thickness was observed in the teriparatide group.
The r2 between percent change of cortical thickness and that
of BR in the teriparatide group was higher than the placebo
group.
As illustrated in Fig. 4, teriparatide improved all geometry
and biomechanical parameters, while maintaining their rela-
tionships with changes in cortical thickness (as in the placebo
Fig. 4 Weekly administration of teriparatide reverses age-related chang-
es at 72 weeks in cortical geometry and biomechanical properties at the
femoral neck. Relationships between percent changes in cortical thick-
ness versus those in cortical cross-sectional area (CSA) (a), perimeter (b),
SM (c), or BR (d) are shown. Solid circles and open circles correspond
to percent changes of individuals in the teriparatide and placebo groups,
respectively. Note that linear regression lines for teriparatide (solid lines)
and placebo (dashed lines) showing the relationship between the percent
change in cortical thickness and those in other parameters, are almost
identical regardless of whether the correlation is positive (a and c) or
negative (b and d). The distribution of closed and open circles in each
quadrant is shown in percentages. Note that with respect to the parameters
with positive correlations (a and c), the relative distribution of open
circles (for placebo) in the third quadrant is shifted to the first quadrant
by weekly teriparatide (closed circles). Similarly, in the case of the
parameters with negative correlations (b and d), relative distribution of
open circles (for placebo) in the second quadrant is shifted to the fourth
quadrant by weekly teriparatide (closed circles), suggesting that weekly
teriparatide reversed age-related changes in proximal femur geometry and
biomechanical properties
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group). However, the distribution patterns of their relation-
ships indicate that the effect of teriparatide is in the exact
opposite direction of age-related skeletal changes. It is sug-
gested, therefore, that compared with the changes in the
placebo group, once-weekly teriparatide injection reverses
age-related deteriorations in bone structure and strength by
increasing cortical thickness/CSA and total vBMD, not in-
creasing cortical perimeter, and improving biomechanical
parameters.
In our previous study which characterized femoral neck
geometry in patients with hip versus trochanteric fractures and
compared them with age-matched controls [7], patients with
femoral neck fracture had a significantly longer hip axis length
(HAL), lower cross-sectional moment of inertia (CSMI), and
higher BR, while those with trochanteric fractures had a
smaller cortical CSA of the femoral neck. Once-weekly
teriparatide may improve all these geometric changes. Taken
together with the present results that SM (calculated as CSMI)
divided by the maximal distance to center of the bone mass
(centroid) increased by approximately 4 %, and BR decreased
approximately 4 % compared to placebo, once-weekly injec-
tion of 56.5 μg teriparatide may have the potential to reduce
the risk of hip fracture.
In the current longitudinal study, we also analyzed the
geometry and biomechanical properties at the inter-
trochanter and shaft regions in addition to those at the femoral
neck. The percent changes in several parameters at the femoral
neck and inter-trochanter were greater at 48 weeks compared
to 72 weeks, while at the femoral shaft, the changes were
greater at 72 weeks compared to 48 weeks, suggesting that the
effects of teriparatide at the shaft take place in a later phase
than those at the femoral neck and inter-trochanter. Endosteal
bone formation might appear later at the purely cortical site,
such as femoral shaft. Similar results were observed in the
DXA-HSA study [9], in which teriparatide seemed to have no
significant effects on femoral shaft geometrical parameters.
A limitation of our study was the small number of subjects;
since all the participating institutes in the TOWER trial were
not equipped with MDCT scanners, the number of subjects
with CT scans was limited. We paid careful attention, for
example, to the CT images and those with artifacts were
excluded from the study. However, the results of this study
were proved by comparison with the placebo group. Another
limitation was that we had no confirmation on the event of hip
fracture, since no new hip fracture was reported in either
group. As an additional limitation, Mindways software was
used for analyzing the geometry of inner and outer surfaces of
the cortex and this method may not currently be the best
available technology for this evaluation. However, we care-
fully applied this program to define the same region of an
individual subject for analysis, using the “Optimize FN Axis”
algorithm. When this algorithm did not work well and differ-
ent regions were obtained, we carefully manually adjusted
both the axis of the femoral neck and the axis of the femoral
shaft, visually comparing the baseline CT image and the
treatment image. In addition, we improved the reproducibility
using the eccentricity registration method for measurement of
the femoral neck.
In conclusion, we have demonstrated (using CT and 3D
analysis) that once-weekly teriparatide increased cortical
thickness and cortical and total CSA, and improved biome-
chanical indices. Moreover, once-weekly teriparatide did not
increase cortical perimeter but seemed to effectively reverse
changes in proximal femur geometry with aging. Taken to-
gether with its anti-fracture efficacy in the spine [5], once-
weekly 56.5 μg teriparatide administration may have the
potential to prevent hip fracture.
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